All News SpectraCure AB

Equities

SPEC

SE0007158118

Delayed Nasdaq Stockholm Other stock markets 06:05:21 2024-05-22 am EDT			5-day change	1st Jan Change
2.535 ^SEK	-3.61%		-12.59%	-34.33%

Feb. 23	Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	CI
Feb. 22	SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SpectraCure takes the next step in the work with the new clinical study	Feb. 23	AQ
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	Feb. 23	CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
A well-accomplished annual audit in accordance with ISO 13485:2016	Jan. 23	AQ
Expert group comments on results of ongoing study	Dec. 19	AQ
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy	Dec. 19	CI
SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!	Nov. 29	PU
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16	CI
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer	Nov. 16	AQ
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer	Nov. 16	CI
SpectraCure : Meet SpectraCure’s board member, Homer Pien!	23-10-31	PU
SpectraCure strengthens presence among urologists	23-10-06	AQ
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®	23-06-27	AQ
SpectraCure Receives an Additional EU Grant	23-06-27	CI
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
SpectraCures signs Letter of Intent with Cheplapharm	22-12-07	AQ
SpectraCures Signs Letter of Intent with Cheplapharm	22-12-07	CI
SpectraCure : First treatment with Q-PRO and integrated image management technology	22-11-24	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News SpectraCure AB

Equities

SPEC

SE0007158118

All News

Filters